Patent Term Application for ZIIHERA® (zanidatamab-hrii), Patent No. 10,000,576 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0372

Patent Term Application for ZIIHERA® (zanidatamab-hrii), Patent No. 10,000,576

Documents

Comments

Description

OPEN

Comment Period OpensFeb 4, 2025

Comment Period ClosesJun 3, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; ZIIHERA FR Doc: 2026-06476	Apr 3, 2026	--

CDER

Patent Term Application for ZIIHERA®

ICE Miller LLP

Zymeworks BC Inc

(zanidatamab-hrii)

Patent No. 10,000,576

OPEN